Yale Study: Online GLP-1 Prescriptions Lack Oversight
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- A Yale researcher published a secret shopper study in the Journal of the American Medical Association on Monday, posing as a patient to document how nearly 50 online telehealth sites prescribe GLP-1 medications for weight loss.
- The study found it is "extraordinarily fast and easy" to obtain a GLP-1 prescription online, capturing what many Americans have experienced firsthand in recent years.
- Direct-to-consumer telehealth companies have grown rapidly in response to surging patient demand for GLP-1s such as semaglutide and tirzepatide.
- GLP-1 shortages fueled a parallel market for compounded versions of the drugs that are not approved by the Food and Drug Administration, further accelerating the online prescribing boom.
- Clinicians and public health experts have raised concerns that lax virtual care practices could put patients at risk, concerns the new study was designed to document empirically.
Why it matters: With nearly 50 telehealth sites examined and peer-reviewed validation from JAMA, regulators and clinicians now have documented evidence that the booming direct-to-consumer market for weight-loss GLP-1s operates with minimal clinical safeguards — increasing pressure on the FDA and telehealth platforms to tighten prescribing standards for drugs like semaglutide and tirzepatide.
